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Abstract
Background: When measuring treatment effect on symptoms, the treatment success variable
should be as responsive as possible. The aim of the study was to investigate the responsiveness of
various treatment success variables in patients with symptoms of heartburn.
Methods: A total of 1640 patients with non-erosive reflux disease (NERD) were treated with
proton pump inhibitors for 4 weeks. Treatment success variables were based on a symptom
questionnaire (Gastrointestinal Symptom Rating Scale) and on investigator-assessed heartburn,
measured at baseline and after 4 weeks of treatment. The rates of treatment success were
compared with patients' perceived change in symptoms, assessed by the Overall Treatment Effect
questionnaire.
Results: Generally, more stringent treatment success criteria (i.e., those demanding the better
response) translated into more responsive treatment success variables. For example, the treatment
success variable 'no heartburn' at 4 weeks was more responsive than the variable 'at most mild
heartburn' at 4 weeks. Treatment success variables based on change from baseline to 4 weeks
were, in general, less responsive than those based on the week 4 assessments only.
Conclusion: In patients with NERD, responsiveness varied among different treatment success
definitions, with more demanding definitions (based on the 4-week assessment) giving better
responsiveness.
Background
The resolution and enduring relief of symptoms in
patients with gastro-esophageal reflux disease (GERD) is
an important treatment goal [1]. Accurate symptom
assessment is of particular importance in patients with
non-erosive reflux disease (NERD), where symptom
measurement is the sole method of evaluating the effec-
tiveness of therapy. To be useful as endpoints in clinical
trials, such measures should be responsive to change, i.e.,
they should reflect patients' changes in their symptom sta-
tus and demonstrate responsiveness to treatment induced
changes over time [2,3].
In clinical trials, symptoms are most often recorded on a
scale, graded from 'no symptoms' to 'very severe symp-
toms', in 4 to 7 categories. These assessments are made
either by the patient, in a diary card or in a questionnaire,
or by an investigator. Such symptom scales may be treated
as continuous variables by scoring the categories (e.g., 'no
symptoms' = 0, 'mild symptoms' = 1, etc.) but they can
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also be used to define a dichotomised treatment success
variable. When a scale is treated as a continuous variable,
responsiveness may be evaluated using indicators such as
the effect size and the standardised response mean, or by
applying anchor-based methods [3]. Evaluation of
responsiveness of symptom scales for upper gastrointesti-
nal symptoms has been reported for scales treated as con-
tinuous variables [4-6].
From these symptom scales various treatment success var-
iables may be derived, e.g., complete symptom resolution
(i.e., no post-treatment symptoms) or at least one score
point improvement since pre-treatment. When compar-
ing treatments in a clinical trial, the results are presented
as percentage of patients with treatment success, e.g., per-
cent patients with complete symptom resolution, in each
treatment group. Such results may be easier to interpret
and communicate than results presented as a mean score
change on a symptom scale.
This study examined responsiveness of different treatment
success variables, with regard to heartburn, in patients
with NERD.
Methods
Patients
Data were collected from patients who had experienced
heartburn as their main GERD symptom for ≥ 6 months.
Patients were enrolled if they had suffered heartburn for ≥
4 days in the week prior to starting the study and had to
have normal endoscopy results (i.e., no esophageal
breaks) within 14 days of starting treatment.
Study design and assessments
Patient data were pooled from two different studies of
similar design and identical entry criteria [7]. In Study A,
patients had received once-daily treatment with esome-
prazole 40 mg, esomeprazole 20 mg or omeprazole 20 mg
and in Study B they had received once-daily treatment
with either esomeprazole 20 mg or omeprazole 20 mg.
Overall heartburn severity (none, mild, moderate or
severe) and the number of days with heartburn, both
referring to the last 7 days, were assessed by the investiga-
tor at baseline and after 4 weeks of treatment.
Additionally, at baseline and after 4 weeks of treatment,
patients answered the Gastrointestinal Symptom Rating
Scale (GSRS) questionnaire, which includes 15 items [8].
The items are grouped into five domains, one of which is
the Reflux domain, composed of a heartburn item and a
regurgitation item. However, investigator assessment of
both frequency and severity was done only for heartburn.
In order to be comparable with this assessment the GSRS
Heartburn item was chosen for this analysis of responsive-
ness. With reference to the previous 7 days, GSRS uses a
Likert scale to assess symptom severity. Categories are
scored from 0 to 6: 'no discomfort at all', 'minor', 'mild',
'moderate', 'moderately severe', 'severe', or 'very severe
discomfort'.
After 4 weeks of treatment, patients also answered the
Overall Treatment Effect (OTE) questionnaire, a question-
naire adapted from the Global Ratings of Change Ques-
tionnaire (GRCQ) with the permission of McMaster
University, Hamilton, Ontario, Canada [9]. In this ques-
tionnaire, patients rated change in heartburn and regurgi-
tation since start of treatment as being 'worse',
'unchanged' or 'better' since study start. If better, then the
degree of improvement was rated in categories: 'almost
the same, hardly better at all', 'a little better', 'somewhat
better', 'moderately better', 'a good deal better', 'a great
deal better' or 'a very great deal better'. If worse, the degree
of deterioration was rated in a corresponding way. For the
purpose of this analysis the original categories were col-
lapsed into the following OTE groups: 'worse' (all 'worse'
categories in OTE), 'unchanged', 'somewhat better'
('almost the same', 'a little' and 'somewhat' better catego-
ries in OTE), 'a good deal better' ('moderately' or 'a good
deal' better categories in OTE), 'a great deal better' and 'a
very great deal better'.
The OTE measures refers to change in both heartburn and
regurgitation, but heartburn is the dominating symptom.
Both at baseline and after 4 weeks, less than 8% of the
patients had more severe regurgitation than heartburn.
The change rated by OTE should thus mainly reflect
changes in heartburn.
Responsiveness
If a patient's health status changes over time, and a varia-
ble is able to reflect these changes, then this variable is
responsive to change. In this evaluation of responsiveness
we used the OTE subgroups described above for assessing
the change in patients' health status. For continuous vari-
ables the magnitude of the effect size or standardised
response mean may be used as a quantitative measure of
responsiveness. Here we examined dichotomous treat-
ment success variables and instead looked at the propor-
tion of patients with treatment success in the different
OTE subgroups.
For effective treatments where a relatively large number of
patients get 'a very great deal better', a quantitative meas-
ure comparing responsiveness of treatment success varia-
bles may be the difference in treatment success rate
between patients recording 'unchanged' and those record-
ing 'a very great deal better' on the OTE questionnaire. The
greater this difference, the better the responsiveness of the
variable. There should also be a consistent increase in
treatment success rate as the level of improvementHealth and Quality of Life Outcomes 2007, 5:32 http://www.hqlo.com/content/5/1/32
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increases. Thus, for patients who state that their symp-
toms have improved since pre-treatment, there should be
a larger treatment success rate than for patients who state
that their symptoms have not improved.
Statistical analysis
The following treatment success variables, based on the 4-
week assessment only, were examined:
- Based on the Heartburn item of GSRS: 3 success varia-
bles, defined as 'no heartburn', 'at most minor heartburn',
and 'at most mild heartburn'
- Based on investigator-assessed heartburn severity: 2 suc-
cess variables, defined as 'no heartburn' and 'at most mild
heartburn'
- Based on investigator-assessed heartburn frequency: 3
success variables, defined as 'at most 1 day', 'at most 2
days' and 'at most 3 days' with heartburn during the last 7
days prior to the 4-week visit.
The following variables, based on improvement from
baseline to 4 weeks, were also examined:
- Improvement in GSRS heartburn item by at least 1 score
unit, at least 2 score units and at least 3 score units
- Improvement in GSRS Heartburn item by at least 50%
- Improvement in investigator-assessed heartburn severity
by at least 1 grade
- Improvement in investigator-assessed heartburn fre-
quency by at least 1, 2 and 3 days.
Results
In total, data from 1640 patients with investigator assess-
ment, GSRS and OTE recordings made on the same day
were included in the analysis. Most patients had no heart-
burn at 4 weeks (61.3% according to investigator's assess-
ment and 60.3% according to GSRS). Baseline
demographics and clinical characteristics are summarised
in Table 1.
Treatment success rates by OTE groups are presented
numerically in Table 2 and graphically in Figures 1, 2, 3,
4. Treatment success variables based on the post-treat-
ment assessments only are shown in Figures 1 (GSRS
Heartburn item) and 2 (investigator-assessed heartburn).
In general, the more stringent (or hard to achieve) the suc-
cess criterion, the better the responsiveness as measured
by the difference in success rates between patients being
'unchanged' and those being 'a very great deal better'
according to OTE. For example, the difference in success
rate between those who were 'a very great deal better'
according to OTE and those who were 'unchanged' was
74.5 percentage points (87.8% minus 13.3%) for the var-
iable 'no heartburn' according to GSRS Heartburn item
(Figure 1 and Table 2). This difference decreased to 61.8
percentage points for the variable 'at most minor heart-
burn' and to 39.3 percentage points for the variable 'at
most mild heartburn'. The general observation that a
more stringent criterion gives better responsiveness in this
population of patients also applied to success variables
based on improvement from baseline, as can be seen in
Figures 3 (GSRS Heartburn item) and 4 (investigator-
assessed heartburn). For example, in Figure 3, the treat-
ment success variable 'at least 1 score unit' improvement
in GSRS Heartburn score is less stringent (or easier to
achieve) than 'at least 2 score units' improvement, which
in turn is less stringent than 'at least 3 score units'
improvement. For these variables the difference in success
rate between those who were 'a very great deal better' and
those who were 'unchanged' was 38.2 percentage points,
63.4 percentage points and 71.4 percentage points,
respectively.
Discussion
Responsiveness relates to the ability to detect changes
when a patient improves or deteriorates. When choosing
a treatment success variable to be used in a clinical trial,
responsiveness is one of the key properties. Patients on a
less effective drug will experience less improvement
(which is captured by the OTE) than patients on a more
effective drug. In order to make the difference in improve-
ment as visible as possible in terms of a difference in treat-
ment success rates, the treatment success variable should
be as responsive as possible.
Table 1: Baseline demographics and clinical characteristics of the 
pooled study population (n = 1640)
Characteristic Patients (%)*
Male:Female 47:53
Age, years
<50 54
50 to <65 34
≥ 65 12
History of heartburn episodes
<12 months 11
1–5 years 35
>5 years 53
Overall heartburn severity during the previous 7 
days (investigator-assessed)
Mild 21
Moderate 62
Severe 18
*Values do not necessarily total 100% due to rounding.Health and Quality of Life Outcomes 2007, 5:32 http://www.hqlo.com/content/5/1/32
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Responsiveness of investigator-assessed heartburn at 4  weeks Figure 2
Responsiveness of investigator-assessed heartburn at 
4 weeks. Treatment success rate for variables based on the 
4-week investigator assessment of heartburn, by Overall 
Treatment Effect classification after 4 weeks of treatment; 
HB, heartburn.
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Table 2: Percentage of patients with treatment success for heartburn by overall treatment effect group
Treatment success definition
Worse
(n = 35)
Unchanged
(n = 181)
Somewhat better
(n = 83)
A good 
deal better
(n = 247)
A great deal 
better
(n = 314)
A very great deal better
(n = 780)
All 
(n = 1640)
GSRS score at 4 weeks
0 (no HB) 5.7 13.3 21.7 32.0 57.6 87.8 60.3
≤ 1 (minor HB) 17.1 35.4 55.4 66.4 84.1 97.2 79.4
≤ 2 (mild HB) 37.1 59.7 86.7 88.3 95.2 99.0 90.4
Inv-assessed severity
0 (no HB) 8.6 14.4 20.5 34.8 61.1 87.4 61.3
≤ 1 (mild HB) 34.3 61.3 85.5 86.6 95.5 98.7 90.1
Inv-assessed frequency
≤ 1 day with HB 8.6 17.1 31.3 44.9 71.0 92.2 67.9
≤ 2 days with HB 8.6 24.9 43.4 56.7 80.3 96.2 74.8
≤ 3 days with HB 17.1 30.4 55.4 70.9 86.9 98.2 80.5
No. of score units improved in GSRS
≥ 1 31.4 60.8 83.1 85.4 91.7 99.0 89.1
≥ 2 28.6 33.7 59.0 70.0 82.8 97.1 79.9
≥ 3 20.0 21.0 39.8 47.0 69.7 92.4 69.1
≥ 50% improvement in GSRS 25.7 25.4 49.4 62.3 78.0 96.8 76.2
≥ 1 grade (Inv) improvement 45.7 68.5 89.2 91.1 96.5 99.0 92.3
Improvement in Inv-assessed frequency
≥ 1 day 42.9 48.1 68.7 85.0 92.0 99.4 87.4
≥ 2 days 28.6 39.2 57.8 77.3 90.1 98.8 83.8
≥ 3 days 17.1 28.7 50.6 66.8 85.0 97.7 78.9
GSRS = Gastrointestinal Symptom Rating Scale; HB = heartburn; Inv = investigator.
Responsiveness of Gastrointestinal Symptom Rating Scale- assessed heartburn at 4 weeks Figure 1
Responsiveness of Gastrointestinal Symptom Rating 
Scale-assessed heartburn at 4 weeks. Treatment suc-
cess rate for variables based on the 4-week assessment of 
the GSRS Heartburn item, by Overall Treatment Effect clas-
sification after 4 weeks of treatment; HB, heartburn.
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When treating patients with symptoms of heartburn with
a proton pum inhibitor, the effect is rather dramatic.
Among the patients examined in this study, 48% (780/
1640, Table 2) rated their change as 'a very great deal bet-
ter'. With almost half of the patients being 'a very great
deal better' we believe that the difference in success rates
between these patients and patients being 'unchanged' is
a relevant measure of responsiveness when comparing dif-
ferent treatment success variables. In other situations,
where patients experience a smaller change, other meas-
ures of responsiveness may be more relevant.
In evaluations of a clinically relevant change the catego-
ries 'almost the same, hardly better at all' and 'almost the
same, hardly worse at all' are usually included in the
'unchanged' group. However, in this evaluation of respon-
siveness we did not include these categories in the
'unchanged' group. Few patients rated their change in
these two categories (8 patients in total) and including
these patients in the unchanged group would have had a
minimal impact on the calculated success rates.
In this study, the treatment success variables with the best
responsiveness were 'at most 1 day with heartburn' (inves-
tigator-assessed) and 'no heartburn' (investigator-assessed
or according to GSRS) and these should be candidates for
use in future GERD trials. The primary variable for the tri-
als that were analysed in this study was in fact 'no heart-
burn' (according to the investigator assessment).
Treatment success variables should also be realistic in
order to be useful in everyday clinical life. For example, a
patient reaching the criterion 'no heartburn' will have less
symptoms than the healthy normal population where
occasional heartburn is common. Allowing for one day
per week with heartburn may be a more realistic outcome
measure.
Change from baseline generally gave a lower responsive-
ness than 4-week assessments. If the heartburn response at
4 weeks depends on the baseline heartburn severity, in
that patients with more severe heartburn tend to have
mild heartburn after treatment, and patients with mild
baseline heartburn tend to have no heartburn after treat-
ment, a success variable based on change from baseline
may be desirable. However, in these trials there was no
such clear tendency. For example, the success rate of the
'no heartburn' variable was 61, 63 and 58 percentage
points, respectively, for patients with mild, moderate and
severe heartburn at baseline.
Previous studies on the responsiveness of symptom
assessments for NERD have been made in terms of mean
score of a symptom scale. This study has evaluated respon-
siveness in terms of percentage of patients with treatment
success with regard to heartburn, and compared the
responsiveness of different treatment success variables.
One finding is that treatment success variables based on
change from baseline to 4 weeks seem to be less respon-
sive than those based on the week 4 assessments only;
another finding is that more stringent treatment success
criteria seems to translate into more responsive treatment
success variables.
Conclusion
To conclude, this study shows that responsiveness varied
among different treatment success definitions with acid-
suppressive therapy in the setting of NERD, with more
Responsiveness of investigator-assessed heartburn, in terms  of improvement from baseline to 4 weeks Figure 4
Responsiveness of investigator-assessed heartburn, in 
terms of improvement from baseline to 4 weeks. 
Treatment success rate for variables based on improvement 
from baseline to 4 weeks, according to investigators' assess-
ment, by Overall Treatment Effect classification after 4 
weeks of treatment.
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Responsiveness of Gastrointestinal Symptom Rating Scale  (GSRS)-assessed heartburn, in terms of improvement from  baseline to 4 weeks Figure 3
Responsiveness of Gastrointestinal Symptom Rating 
Scale (GSRS)-assessed heartburn, in terms of 
improvement from baseline to 4 weeks. Treatment 
success rate for variables based on improvement from base-
line to 4 weeks according to the GSRS Heartburn item, by 
Overall Treatment Effect classification after 4 weeks of treat-
ment.
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stringent definitions based on the 4-week assessment giv-
ing better responsiveness.
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